Respiratory & Immunology皇冠官网平台
Senior Vice President and Global Head of Respiratory & Immunology Late Stage Development, BioPharmaceuticals R&D
Senior Vice President and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D
Hear from Chris皇冠官网平台
"AstraZeneca is a great place to work if you want to be challenged and if you want to have the ability to see the impact of your work towards developing medicines for patients with respiratory diseases like COPD."
Chris Miller - VP, Biometrics & Information Sciences, Respiratory & Immunology
Hear from Brad皇冠官网平台
"I have worked in immunology for over 15 years, but when I joined AstraZeneca’s global commercial organization I was especially excited by the chance to work on a potentially transformative medicine for lupus and other diseases that have had so little therapeutic advances in the past several decades. "
Brad Nohe - Head of Commercial, Head of Patient Service & Delivery, Respiratory Biologics, Respiratory & Immunology
Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.
Accolate, Accoleit, Vanticon皇冠官网平台
terbutaline in a dry powder inhaler
aclidinium, a LAMA
budesonide inhalation suspension
Veeva ID: Z4-23796
Date of next review: April 2022